Dr. Axel Hoos is CEO of Scorpion Therapeutics, a next-generation oncology company focused on precision medicine 2.0 with the potential to address many of the current white spaces in cancer care.
Previously, he was the senior vice president of Oncology R&D at GlaxoSmithKline Pharmaceuticals (GSK). Previously, while he was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS), Dr. Hoos helped played a pivotal role in the approval of the first FDA-approved checkpoint immunotherapy, the anti-CTLA-4 ipilimumab. In his current role, he directs discovery and development at GSK and is focused on building their immuno-oncology portfolio across antibodies, small molecules, bispecific molecules, and cell and gene therapies.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Hoos serves as chairman of the Cancer Immunotherapy Consortium (CIC) Steering Committee.
The aim is to create transformational medicines, with bigger effects for mono-therapies or combinations.
Let's spread the word about Immunotherapy! Click to share this page with your community.